AstraZeneca can still compound into 2035, but the distribution of outcomes is much wider than the market often admits. The most defensible range is $265 to $350, because the stock has to navigate ...
AstraZeneca still deserves a constructive long-term rating, but the next five years are unlikely to repeat the last decade's 15.2% annualized share-price run. A disciplined 2030 base case is $220 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results